Haloperidol Esteve

Haloperidol Esteve is a prescription medication that contains the active ingredient haloperidol. It is formulated for intramuscular administration and is marketed in the European Union. As a butyrophenone antipsychotic, it works by blocking dopamine D2 receptors. The product is supplied without a brand name and is intended for use under medical supervision for approved psychiatric indications, especially when rapid symptom control is needed in clinical settings.

Haloperidol Esteve is indicated for several acute psychiatric conditions where rapid control of symptoms is required, and it is often used in inpatient or emergency environments.

- Schizophrenia, especially during acute exacerbations or when oral therapy is not feasible. - Acute psychotic episodes related to bipolar disorder or major depressive disorder with psychotic features. - Severe agitation, aggression, or violent behavior requiring rapid calming in emergency or psychiatric units. - Pre‑operative sedation for patients at risk of delirium or postoperative psychosis. - Management of hyperactive delirium in intensive care or postoperative settings.

The safety profile of Haloperidol Esteve includes a range of adverse effects that vary in frequency and severity; patients should be monitored regularly for both common and potentially serious reactions.

Common: - Drowsiness or sedation, which may affect alertness and coordination. - Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or dystonia. - Dry mouth, increased salivation, or other anticholinergic‑like effects. - Constipation, abdominal discomfort, or reduced gastrointestinal motility.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by fever, muscle rigidity, and autonomic instability. - Cardiac arrhythmias, including QT‑interval prolongation and torsades de pointes, especially in patients with pre‑existing heart conditions. - Severe hypotension, syncope, or sudden loss of consciousness.

When prescribing Haloperidol Esteve, clinicians should consider several precautionary measures to minimize risks and ensure appropriate use.

- Assess patient history for cardiovascular disease, electrolyte imbalances, or prolonged QT interval before initiating therapy. - Use the lowest effective dose and limit duration, particularly in elderly patients, to reduce the risk of extrapyramidal symptoms. - Monitor for signs of neuroleptic malignant syndrome, especially during the first few days of treatment. - Evaluate liver and renal function periodically, as impairment may affect drug clearance. - Exercise caution in patients with a history of seizures, Parkinson’s disease, or severe depression. - Avoid abrupt discontinuation to prevent withdrawal or rebound psychosis.

Haloperidol Esteve can interact with other medications, altering its efficacy or increasing the likelihood of adverse effects; careful review of a patient’s drug regimen is essential.

Avoid: - Use with other dopamine antagonists or high‑potency antipsychotics, which may worsen extrapyramidal effects. - Combine with QT‑prolonging drugs (e.g., certain antiarrhythmics, macrolide antibiotics) because of increased arrhythmia risk. - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) that raise haloperidol levels.

Use with caution: - CYP2D6 substrates (metoprolol, codeine) as haloperidol may alter their metabolism. - CNS depressants such as benzodiazepines or opioids, which can increase sedation. - Lithium, because combined use may heighten neurotoxicity risk.